Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension

Objective A sustained blood pressure elevation is associated with an increased risk of new-onset diabetes mellitus. Whether this is the case also in white-coat and masked hypertension is unknown. Methods In 1412 individuals of the Pressioni Arteriose Monitorate E Loro Associazioni study stratified for sex and age decades, we measured office, home and 24-h ambulatory blood pressure together with fasting plasma glucose and other metabolic variables. This allowed to identify patients with white-coat, masked, sustained hypertension and true normotension. Results Over a 10-year period, the increase in plasma glucose and the incidence of new-onset diabetes (plasma glucose ≥126 mg/dl or use of antidiabetic drugs) was significantly greater in individuals with white-coat and masked hypertension than in those with ‘true’ normotension (age and sex-adjusted risk 2.9 and 2.7, respectively), the increase being similar to that of sustained hypertensive individuals. The adjusted risk showed a marked increase when development of an impaired fasting glucose condition was also considered, and the results were similar when individuals reporting antihypertensive drug treatment were excluded or white-coat and masked hypertension were identified by office versus home blood pressure. The increased risk of new-onset diabetes become no more significant when data were adjusted for initial blood glucose and BMI, which, at a multivariate analysis, were the most significant predictors of this condition, with only a small although significant contribution of the initial blood pressure. Conclusion Thus, white-coat and masked hypertension are associated with a long-term greater progression of blood glucose abnormalities and an increased risk of developing diabetes. This is largely accounted for by the metabolic abnormalities that are frequent components of these conditions.

[1]  G. Mancia,et al.  The metabolic syndrome in hypertension: European society of hypertension position statement , 2008, Journal of hypertension.

[2]  G. Mancia,et al.  Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population , 2008, Journal of hypertension.

[3]  J. Lekakis,et al.  Target organ damage in "white coat hypertension" and "masked hypertension". , 2008, American journal of hypertension.

[4]  J. Staessen,et al.  Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7030 individuals , 2007, Journal of hypertension.

[5]  K. Kario,et al.  Masked Hypertension: A Review , 2007, Hypertension Research.

[6]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[7]  Satoko Nakamura,et al.  Masked hypertension and target organ damage in treated hypertensive patients. , 2006, American journal of hypertension.

[8]  Roberto Sega,et al.  Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure , 2006, Hypertension.

[9]  R H Fagard,et al.  Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice , 2005, Journal of Human Hypertension.

[10]  F. Messerli,et al.  Masked hypertension and white-coat hypertension: therapeutic navigation between scylla and charybdis. , 2005, Journal of the American College of Cardiology.

[11]  C. Papamichael,et al.  White-coat and masked hypertension in children: association with target-organ damage , 2005, Pediatric Nephrology.

[12]  G. Mancia,et al.  Relationship of Office, Home, and Ambulatory Blood Pressure to Blood Glucose and Lipid Variables in the PAMELA Population , 2005, Hypertension.

[13]  Yutaka Imai,et al.  Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. , 2005, Journal of hypertension.

[14]  Empar Lurbe,et al.  Prevalence, Persistence, and Clinical Significance of Masked Hypertension in Youth , 2005, Hypertension.

[15]  J. Schwartz,et al.  Short- and Long-Term Incidence of Stroke in White-Coat Hypertension , 2005, Hypertension.

[16]  J. Polónia,et al.  Relationship between aortic stiffness and cardiovascular risk factors in a population of normotensives, white-coat normotensives, white-coat hypertensives, sustained hypertensives and diabetic patients. , 2004, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[17]  Ralph B D'Agostino,et al.  Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. , 2002, Diabetes care.

[18]  M. Nieminen,et al.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , 2002, Journal of hypertension.

[19]  E. O’Brien,et al.  Cardiovascular Risk In White-coat and Sustained Hypertensive Patients , 2002, Blood pressure.

[20]  G. Mancia,et al.  Alterations of Cardiac Structure in Patients With Isolated Office, Ambulatory, or Home Hypertension: Data From the General Population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study) , 2001, Circulation.

[21]  E. Frohlich,et al.  Diabetes, Hypertension, and Cardiovascular Disease: An Update , 2001, Hypertension.

[22]  R. Asmar,et al.  Arterial distensibility in subjects with white‐coat hypertension with and without diabetes or dyslipidaemia: comparison with normotensives and sustained hypertensives , 2000, Blood pressure monitoring.

[23]  G. Mancia,et al.  Task force V: White-coat hypertension , 1999 .

[24]  J D Swales,et al.  Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pressure monitoring in essential hypertension. , 1999, Circulation.

[25]  G. Mancia,et al.  Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. , 1997, Hypertension.

[26]  G. Schillaci,et al.  Prognostic significance of the white coat effect. , 1997, Hypertension.

[27]  G. Mancia,et al.  White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? , 1996, Journal of hypertension.

[28]  M. Weber,et al.  Diagnosis of mild hypertension by ambulatory blood pressure monitoring. , 1994, Circulation.

[29]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[30]  M. Kornitzer,et al.  The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): A major international Collaboration , 1988 .